Show Summary Details
Page of

Pharmacogenomics and Precision Psychiatry 

Pharmacogenomics and Precision Psychiatry
Pharmacogenomics and Precision Psychiatry

Julia C. Stingl

and Gonzalo Laje

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 May 2022

Molecular medicine has opened new possibilities of personalized approaches in drug therapy. The development of evidence-based pharmacogenetic guidelines to steer therapy has slowly entered the field of psychiatric therapeutics. Some of the reasons behind the limited progress in psychiatric pharmacogenomics include the broad definition of clinical syndromes, limited knowledge of psychiatric pathophysiology, and limited understanding of psychotropics’ mechanisms of action. Pharmacogenomic markers have been reported for both pharmacodynamic and pharmacokinetic genes. However, only genetic variation in pharmacokinetic genes has shown to be helpful in clinical practice. There is little consensus as to when and if pharmacogenetic tests should be used in psychiatry. There are limited evidence-based dosing guidelines available for actionable gene–drug pairs. Future work in psychiatry may deepen our understanding of the biological underpinnings of psychiatric syndromes and provide the potential for individual tailored therapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.